Related Experiment Videos
[Right ventricular tachyarrhythmias--diagnostics and therapy].
M Paul1, E Schulze-Bahr, L Eckardt
1Medizinische Klinik und Poliklinik C, Kardiologie und Angiologie, Universitätsklinikum Münster, Albert-Schweitzer-Strasse 33, 48149 Münster. mapaul@uni-muenster.de
Herzschrittmachertherapie & Elektrophysiologie
|December 20, 2005
Summary
Young patients with right ventricular tachyarrhythmias face sudden cardiac death risks from conditions like ARVC, RVOVT, and Brugada syndrome. Early diagnosis and tailored treatments are crucial for managing these rare cardiac diseases.
Area of Science:
- Cardiology
- Electrophysiology
- Genetics
Context:
- Right ventricular tachyarrhythmias affect young, seemingly healthy individuals.
- Rare cardiac conditions such as arrhythmogenic right ventricular cardiomyopathy (ARVC), idiopathic right ventricular outflow-tract tachycardia (RVOVT), and Brugada syndrome (BrS) are implicated.
- These conditions carry a risk of sudden cardiac death.
Purpose:
- To review the pathogenesis, diagnosis, treatment, and prognosis of right ventricular tachyarrhythmia-associated diseases.
- To highlight the importance of detailed investigations for individualized management.
- To provide a summary of current literature for clinicians and researchers.
Summary:
- Ventricular tachyarrhythmias in young patients often stem from ARVC, RVOVT, or BrS.
- Despite differing diagnostic and prognostic profiles, all pose a risk of sudden cardiac death.
- Management strategies include antiarrhythmic drugs, catheter ablation, and implantable cardioverter-defibrillators.
Impact:
- Informed clinical decision-making for managing rare right ventricular tachyarrhythmia causes.
- Improved patient outcomes through early diagnosis and tailored therapeutic regimens.
- Reduced incidence of sudden cardiac death in affected young individuals.